Loading...
NPI 1639879034 · Deerfield Beach, FL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Reliable Results Labs Inc is a clinical medical laboratory provider located in Deerfield Beach, Florida. This profile covers 67 Medicare and 13 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Reliable Results Labs Inc |
| Address | 600 Fairway Dr Ste 104 |
| City | Deerfield Beach |
| State | FL |
| ZIP | 33441 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | March 6, 2023 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $11.6M |
| Medicaid | $6.7K |
RELIABLE RESULTS LABS INC appears to operate primarily as a genomic and specialized clinical diagnostic laboratory: its top Medicare revenue contributors are high-complexity genomic panel codes (81440, 81419, 81443) and multiple single-gene sequencing tests, which indicates a service line focused on genetic sequencing panels and targeted molecular diagnostics rather than routine chemistry or pathology testing. The presence of large volumes for panel and gene-specific CPTs suggests the lab performs technical sequencing workflows for inherited conditions, oncology, and neurologic indications.
Medicare revenue is the dominant payer relationship for this NPI: lifetime Medicare revenue is $11.6M versus total Medicaid revenue of $6.7K, indicating the provider is functionally single-payer at scale with Medicare comprising essentially all billed revenue. This skew implies the lab’s commercial and Medicaid footprint is minimal or that its contracts/referrals concentrate on Medicare beneficiaries.
Revenue concentration on Medicare is high: the precomputed top 3 Medicare codes account for 45.1% of the provider’s total Medicare revenue, showing nearly half of Medicare dollars derive from a small set of high-value genomic panels (notably 81440, 81419, 81443). For Medicaid, revenue is extremely concentrated as well: the top 3 Medicaid codes account for 71.5% of Medicaid revenue, but given the tiny Medicaid total ($6.7K) this represents a very small absolute dollar pool concentrated in a few genetic test codes.
Competitive standing on key Medicare panel codes is strong nationally: 81440 ($1.9M, 18.0% of Medicare revenue) ranks #2 of 13 providers nationally and is characterized as notably above typical national volume; 81443 ($1.4M, 13.3%) also ranks #2 of 14 and is notably above typical national volume. 81419 ($1.5M, 13.9%) ranks #3 of 27 at the 92nd percentile, which together signal RELIABLE RESULTS LABS is a major national participant for several specialized genomic panels rather than a low-volume local lab.
For other common molecular and infectious codes the provider shows broad testing volume but more typical standing: codes such as 87798 (26.3K claims, $894.4K, 8.3% of Medicare revenue) and 87631 (1.2K claims, $163.2K, 1.5%) are high-count items where the provider ranks within large national cohorts (95th and 96th percentiles respectively) and are described as typical, unremarkable volume. This mix indicates the lab pairs niche, high-revenue genomic panels with higher-throughput, lower-priced molecular assays.
Medicaid activity is de minimis and not competitive statewide: total Medicaid revenue is $6.7K with leading Medicaid codes (81419 and 81321) each contributing roughly 28% of that small total, but those in-state ranks are low (81419 ranks #6 of 6 in-state; 81321 ranks #13 of 15), indicating limited Medicaid market presence and minimal influence on Florida’s Medicaid laboratory supply. Several Medicaid-listed codes show claims but $0 revenue reported for Medicaid (e.g., 81311, 81238, 81279), underscoring that billed activity to Medicaid is negligible in dollars.
The provider’s NPI was enumerated on 2023-03-06 (~3 years ago), so this organization is relatively recent in Medicare/Medicaid provider files. Despite short tenure, the lab has quickly established meaningful Medicare revenue and attained high national rank on several complex genomic panel codes, suggesting rapid operational scale-up in specialized sequencing services.
Taken together, the profile indicates a specialty molecular/genomics operator that relies heavily on a few high-value panel CPTs for Medicare revenue, operates at national-scale volume for select genomic tests (notably 81440 and 81443), and maintains only minimal Medicaid billing. For payers and network planners, this pattern points to a partner whose core competency is advanced genomic testing for Medicare populations rather than broad-based Medicaid lab coverage.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
67 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81440 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least 100 mitochondrial genes encoded in the nucleus, including 19 specific… | 590 | $3,250 | $1.9M |
| 81419 | The lab analyst performs the technical lab test on a specimen such as blood to conduct a genomic sequence analysis panel. The test evaluates the genetic sequences of at least the 24 genes listed in… | 620 | $2,400 | $1.5M |
| 81443 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least 15 genes, such as the 20 gene examples listed in the code descriptor. The… | 590 | $2,400 | $1.4M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 26,310 | $30 | $894.4K |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 920 | $590 | $537.9K |
| 81223 | The lab analyst performs the technical lab test to analyze the entire gene sequence for cystic fibrosis transmembrane conductance regulator gene, also known as CFTR. | 1,000 | $490 | $488.9K |
| 81307 | The lab analyst performs the technical lab test on a specimen such as blood, to analyze the entire gene sequence for the partner and localizer of BRCA2 (PALB2) gene. | 750 | $650 | $484.3K |
| 81249 | The lab analyst performs the technical lab test to analyze known the full gene sequence of the glucose–6–phosphate dehydrogenase (G6PD) gene. | 780 | $590 | $458.6K |
| 81321 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the phosphatase and tensin homolog, or PTEN, gene. | 750 | $590 | $442.8K |
| 81311 | The lab analyst performs the technical lab test to analyze variants in exon 2, such as codons 12 and 13, and exon 3, such as codon 61, for the neuroblastoma RAS viral, v–ras, oncogene homolog, also… | 1,240 | $290 | $360.2K |
Showing 1–10 of 67
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 67 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
67 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81440 | 1 | 10 | 170 | $3,240 | $658.4K |
| 81307 | 9 | 30 | 320 | $660 | $508.3K |
| 81443 | 1 | 10 | 170 | $2,400 | $481.7K |
| 81321 | 9 | 30 | 430 | $580 | $467.7K |
| 81238 | 7 | 20 | 330 | $590 | $440.3K |
| 81419 | 1 | 10 | 90 | $2,400 | $434.1K |
| 81249 | 7 | 20 | 290 | $590 | $383.1K |
| 81223 | 6 | 20 | 340 | $490 | $329.3K |
| 81351 | 13 | 20 | 210 | $630 | $307.8K |
| 81334 | 7 | 20 | 390 | $320 | $295.7K |
Showing 1–10 of 67
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
13 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81419 | The lab analyst performs the technical lab test on a specimen such as blood to conduct a genomic sequence analysis panel. The test evaluates the genetic sequences of at least the 24 genes listed in… | 10 | $150 | $1.9K |
| 81321 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the phosphatase and tensin homolog, or PTEN, gene. | 30 | $70 | $1.9K |
| 81317 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the postmeiotic segregation increased 2 [S. cerevisiae], or PMS2 gene. | 20 | $40 | $1K |
| 81298 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 6 [E. coli], or MSH6 gene. | 20 | $30 | $720 |
| 81448 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least five peripheral–neuropathy–related genes, such as the eight gene examples… | 20 | $30 | $510 |
| 81339 | The lab analyst performs the technical lab test on a specimen such as blood to analyze specific gene sequences of the MPL (MPL proto–oncogene, thrombopoietin receptor) gene, such as exon 10, which… | 10 | $20 | $300 |
| 81345 | The lab analyst performs the technical lab test to analyze targeted genes, such as the promotor region for the telomerase reverse transcriptase gene (TERT). | 50 | $10 | $290 |
| 81250 | The lab analyst performs the technical lab test to detect the presence of specific changes in the gene for glucose–6–phosphatase, catalytic subunit, also known as G6PC. | 10 | $10 | $90 |
| 81233 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for Bruton’s tyrosine kinase (BTK). | 10 | $0 | $0 |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 50 | $0 | $0 |
Showing 1–10 of 13
How this provider's Medicaid billing volume and revenue compare to other Florida providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Florida median
13 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81317 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the postmeiotic segregation increased 2 [S. cerevisiae], or PMS2 gene. | 9 | 10 | 70 | $60 | $10.3K |
| 81321 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the phosphatase and tensin homolog, or PTEN, gene. | 13 | 20 | 80 | $40 | $10.1K |
| 81298 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 6 [E. coli], or MSH6 gene. | 9 | 10 | 80 | $50 | $9.4K |
| 81311 | The lab analyst performs the technical lab test to analyze variants in exon 2, such as codons 12 and 13, and exon 3, such as codon 61, for the neuroblastoma RAS viral, v–ras, oncogene homolog, also… | 5 | 10 | 60 | $30 | $5.7K |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 8 | 10 | 60 | $30 | $4.9K |
| 81279 | The lab analyst performs the technical lab test on a specimen such as blood to analyze specific gene sequences of the JAK2 (Janus kinase 2) gene, such as exons 12 and 13, which may be associated with… | 13 | 10 | 70 | $20 | $3.9K |
| 81339 | The lab analyst performs the technical lab test on a specimen such as blood to analyze specific gene sequences of the MPL (MPL proto–oncogene, thrombopoietin receptor) gene, such as exon 10, which… | 9 | 10 | 50 | $10 | $3.7K |
| 81345 | The lab analyst performs the technical lab test to analyze targeted genes, such as the promotor region for the telomerase reverse transcriptase gene (TERT). | 7 | 10 | 80 | $10 | $3K |
| 81419 | The lab analyst performs the technical lab test on a specimen such as blood to conduct a genomic sequence analysis panel. The test evaluates the genetic sequences of at least the 24 genes listed in… | 6 | 10 | 20 | $50 | $1.8K |
| 81250 | The lab analyst performs the technical lab test to detect the presence of specific changes in the gene for glucose–6–phosphatase, catalytic subunit, also known as G6PC. | 7 | 10 | 90 | $10 | $1.6K |
Showing 1–10 of 13
Other providers in the same ZIP code as Reliable Results Labs Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Butterfly Effects, LLC | FL | Early Intervention Provider Agency | $0 | $18.3M |
| Total Renal Care Inc | FL | End-Stage Renal Disease (ESRD) Treatment Clinic/Center | $0 | $10.4M |
| Prince Laboratories Limited Liability Company | FL | Clinical Medical Laboratory | $4.6M | $1.2K |
| Mark Mitchell | FL | Emergency Medicine Physician | $1.9M | $38.2K |
| David Van Roekel | FL | Diagnostic Radiology Physician | $94.3K | $0 |
| William Mazzei | FL | Family Medicine Physician | $68.2K | $0 |
| Laura Haughie | FL | Physical Therapist | $52.3K | $0 |
| Philip Zwiebel | FL | Anesthesiology Physician | $23.7K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.